Evaluation of Keishi-bukuryo-gan in a diabetic nephropathy model by comparison with aminoguanidine, butylated hydroxytoluene and captopril.
|
Accession number;03A0126862
|
| Title;Evaluation of Keishi-bukuryo-gan in a diabetic nephropathy model by comparison with aminoguanidine, butylated hydroxytoluene and captopril. |
| Author;
NAKAGAWA T
(Toyama Medical And Pharmaceutical Univ., Toyama, Jpn)
YOKOZAWA T
(Toyama Medical And Pharmaceutical Univ., Toyama, Jpn)
OYA T
(Toyama Medical And Pharmaceutical Univ., Toyama, Jpn)
SASAHARA M
(Toyama Medical And Pharmaceutical Univ., Toyama, Jpn)
TERASAWA K
(Toyama Medical And Pharmaceutical Univ., Toyama, Jpn)
|
Journal Title;Journal of Traditional Medicines
|
Journal Code:Y0941A
|
ISSN:1340-6302
|
|
VOL.19;NO.6;PAGE.200-208(2002)
|
| Figure&Table&Reference;FIG.4, TBL.5, REF.31 |
| Pub. Country;Japan |
| Language;English |
| Abstract;A study was done to investigate whether Keishi-bukuryo-gan can delay the progression of diabetic nephropathy in an experimentally induced diabetic nephropathy model. The efficacy of Keishi-bukuryo-gan against renal functional and structural changes and its influence on accumulation of advanced glycation end-products (AGEs) and oxidative stress were also examined by comparison with aminoguanidine (an AGEs inhibitor), butylated hydroxytoluene (BHT; an antioxidant) and captopril (an angiotensin converting enzyme inhibitor). Treatment with Keishi-bukuryo-gan for 10 weeks preserved renal function, as assessed in terms of proteinuria and serum creatinine, and prevented the morphological changes peculiar to diabetic nephropathy. However, its renoprotective activity was inferior to that of captopril and comparable to that of aminoguanidine. BHT lacked any of these effects. On the other hand, renal AGEs accumulation and oxidative stress were significantly enhanced in rats with untreated diabetic nephropathy compared with normal rats. Keishi-bukuryo-gan, captopril and BHT showed significant reduction of AGEs levels, but not to the extent shown by aminoguanidine. Renal lipid peroxidation levels were significantly lowered in the groups given Keishi-bukuryo-gan and captopril, but not to the extent shown in the rats given BHT. The reduction of serum lipid peroxidation levels by captopril was stronger than that by BHT. The effects of Keishi-bukuryo-gan and aminoguanidine on serum lipid peroxidation levels were similar to those of BHT. These results suggest that the pharmaceutical characteristics of Keishi-bukuryo-gan may differ from those of the other three medicines examined. (author abst.) |
|
|
|
Related Articles;
|
|
